Answer
Probenecid, a strong OAT3 inhibitor, approximately doubles baricitinib exposure (AUC) without changing tmax or Cmax; the recommended baricitinib dose should therefore be halved in patients taking probenecid.
Sources for this answer
- Baricitinib LillyEli Lilly and Company Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated
Sources checked